Semler Scientific (SMLR) reported Q2 EPS of $0.19, $0.04 better than the analyst estimate of $0.15. Revenue for the quarter came in at $5.58 million versus the consensus estimate of $5.7 million.

"It is our intent to provide cost efficient and practical means for our customers to better care for their patients," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. "We believe that the clinical benefits of using our product are driving adoption and expansion in the medical marketplace."

• Revenues of $5,579,000, an increase of $1,972,000, or 55%, compared to $3,607,000
• Cost of revenues of $615,000, a decrease of $109,000, or 15%, compared to $724,000. As a percentage of revenues, cost of revenues was 11% compared to 20%
• Total operating expenses, which includes cost of revenues, of $4,033,000, an increase of $502,000, or 14%, compared to $3,531,000
• Net income of $1,468,000, or $0.24 per basic share and $0.19 per diluted share, an increase of $1,509,000, compared to a net loss of $41,000, or $0.01 loss per share (basic and diluted). As a percentage of revenues, net income was 26%

For earnings history and earnings-related data on Semler Scientific (SMLR) click here.